NCT04177355: Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults |
|
|
| Completed | 1 | 127 | US | BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571 | National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Access to Advanced Health Institute (AAHI), Dynavax Technologies Corporation, Fred Hutchinson Cancer Center | HIV Infections | 11/24 | 11/24 | | |
